325 related articles for article (PubMed ID: 19445562)
1. Medroxyprogesterone acetate in the management of cancer cachexia.
Madeddu C; Macciò A; Panzone F; Tanca FM; Mantovani G
Expert Opin Pharmacother; 2009 Jun; 10(8):1359-66. PubMed ID: 19445562
[TBL] [Abstract][Full Text] [Related]
2. Effects of medroxyprogesterone acetate on food intake, body composition, and resting energy expenditure in patients with advanced, nonhormone-sensitive cancer: a randomized, placebo-controlled trial.
Simons JP; Schols AM; Hoefnagels JM; Westerterp KR; ten Velde GP; Wouters EF
Cancer; 1998 Feb; 82(3):553-60. PubMed ID: 9452274
[TBL] [Abstract][Full Text] [Related]
3. Cytokine activity in cancer-related anorexia/cachexia: role of megestrol acetate and medroxyprogesterone acetate.
Mantovani G; Macciò A; Lai P; Massa E; Ghiani M; Santona MC
Semin Oncol; 1998 Apr; 25(2 Suppl 6):45-52. PubMed ID: 9625383
[TBL] [Abstract][Full Text] [Related]
4. Treatment of cancer cachexia in mice by combination of dsRNA-dependent protein kinase inhibitor and medroxyprogesterone acetate.
Chen SZ; Zhang YL
Oncol Rep; 2012 Feb; 27(2):579-84. PubMed ID: 22076029
[TBL] [Abstract][Full Text] [Related]
5. Medroxyprogesterone acetate inhibits interleukin 6 secretion from KPL-4 human breast cancer cells both in vitro and in vivo: a possible mechanism of the anticachectic effect.
Kurebayashi J; Yamamoto S; Otsuki T; Sonoo H
Br J Cancer; 1999 Feb; 79(3-4):631-6. PubMed ID: 10027341
[TBL] [Abstract][Full Text] [Related]
6. Randomised phase III clinical trial of 5 different arms of treatment on 332 patients with cancer cachexia.
Mantovani G
Eur Rev Med Pharmacol Sci; 2010 Apr; 14(4):292-301. PubMed ID: 20496538
[TBL] [Abstract][Full Text] [Related]
7. Randomized phase III clinical trial of five different arms of treatment for patients with cancer cachexia: interim results.
Mantovani G; Macciò A; Madeddu C; Gramignano G; Serpe R; Massa E; Dessì M; Tanca FM; Sanna E; Deiana L; Panzone F; Contu P; Floris C
Nutrition; 2008 Apr; 24(4):305-13. PubMed ID: 18262758
[TBL] [Abstract][Full Text] [Related]
8. [Recent development in research and management of cancer anorexia-cachexia syndrome].
Inui A
Gan To Kagaku Ryoho; 2005 Jun; 32(6):743-9. PubMed ID: 15984510
[TBL] [Abstract][Full Text] [Related]
9. Cytokine involvement in cancer anorexia/cachexia: role of megestrol acetate and medroxyprogesterone acetate on cytokine downregulation and improvement of clinical symptoms.
Mantovani G; Macciò A; Lai P; Massa E; Ghiani M; Santona MC
Crit Rev Oncog; 1998; 9(2):99-106. PubMed ID: 9973244
[TBL] [Abstract][Full Text] [Related]
10. [Feeding-related disorders in medicine, with special reference to cancer anorexia-cachexia syndrome].
Inui A
Rinsho Byori; 2006 Oct; 54(10):1044-51. PubMed ID: 17133993
[TBL] [Abstract][Full Text] [Related]
11. An update on promising agents for the treatment of cancer cachexia.
Madeddu C; Mantovani G
Curr Opin Support Palliat Care; 2009 Dec; 3(4):258-62. PubMed ID: 19667995
[TBL] [Abstract][Full Text] [Related]
12. The cancer cachexia syndrome.
Puccio M; Nathanson L
Semin Oncol; 1997 Jun; 24(3):277-87. PubMed ID: 9208884
[TBL] [Abstract][Full Text] [Related]
13. Anti-cytokine strategies for the treatment of cancer-related anorexia and cachexia.
Penna F; Minero VG; Costamagna D; Bonelli G; Baccino FM; Costelli P
Expert Opin Biol Ther; 2010 Aug; 10(8):1241-50. PubMed ID: 20594117
[TBL] [Abstract][Full Text] [Related]
14. [Croatian guidelines for use of eicosapentaenoic acid and megestrol acetate in cancer cachexia syndrome].
Krznarić Z; Juretić A; Samija M; Dintinjana RD; Vrdoljak E; Samarzija M; Kolacek S; Vrbanec D; Prgomet D; Ivkić M; Zelić M;
Lijec Vjesn; 2007 Dec; 129(12):381-6. PubMed ID: 18383739
[TBL] [Abstract][Full Text] [Related]
15. Cancer cachexia: it's time for more clinical trials.
Bossola M; Pacelli F; Tortorelli A; Doglietto GB
Ann Surg Oncol; 2007 Feb; 14(2):276-85. PubMed ID: 17094025
[TBL] [Abstract][Full Text] [Related]
16. [Current views on use of megestrol acetate in oncology practice].
Vyzula R
Vnitr Lek; 1997 Apr; 43(4):250-5. PubMed ID: 9601846
[TBL] [Abstract][Full Text] [Related]
17. [Standards, Options and Recommendations (SOR) for the use of appetite stimulants in oncology. Work group. Federation of the French Cancer Centres (FNCLCC)].
Desport JC; Blanc-Vincent MP; Gory-Delabaere G; Bachmann P; Béal J; Benamouzig R; Colomb V; Kere D; Melchior JC; Nitenberg G; Raynard B; Scheiner S; Senesse P
Bull Cancer; 2000 Apr; 87(4):315-28. PubMed ID: 10827350
[TBL] [Abstract][Full Text] [Related]
18. The cancer anorexia-cachexia syndrome.
Nelson KA
Semin Oncol; 2000 Feb; 27(1):64-8. PubMed ID: 10697022
[TBL] [Abstract][Full Text] [Related]
19. Anorexia and cachexia in advanced cancer patients.
Vigano A; Watanabe S; Bruera E
Cancer Surv; 1994; 21():99-115. PubMed ID: 8565002
[TBL] [Abstract][Full Text] [Related]
20. Cachexia and anorexia.
Mantovani G
Support Care Cancer; 2000 Nov; 8(6):506-9. PubMed ID: 11094998
[No Abstract] [Full Text] [Related]
[Next] [New Search]
